logo
logo

Gameto Raises $23M To Redefine Reproductive Longevity With Reprogrammed Ovarian Cells

Jan 10, 2022•over 3 years ago

Amount Raised

$23 Million

Description

Gameto, a biotechnology start-up solving the problem of accelerated ovarian aging to change the trajectory of women's health and equality, today announced that it has raised a $20 million in Series A funding led by Future Ventures, with participation from Bold Capital Partners, Lux Capital, Plum Alley, TA Ventures, Overwater Ventures, Robert Nelsen and Anne Wojcicki. Gameto also raised $3 million in Seed funding in March 2020 from a range of notable investors including Jack Abraham, SALT Fund, FJ Labs, Dan Rose and Brian Armstrong.

Company Information

Company

Gameto

About

Based in New York and Boston, Gameto is a biotechnology company translating the impact of ovarian aging to develop solutions to improve fertility and stop the impact of menopause on female health. Gameto brings together an experienced scientific management team with vision and passion to develop groundbreaking platforms for women's health. Gameto is led by physician turned entrepreneur, Dina Radenkovic, as CEO and serial entrepreneur and a leader in the fertility space, Martin Varsavsky, as Chairman. For more information, go to www.gametogen.com or contact brielle@gametogen.com. SOURCE Gameto

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech